BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
No abstract available

Keywords: BRCA reversion; Circulating tumor DNA; Metastatic breast cancer; PARP inhibitor; ctDNA.

Publication types

  • Case Reports

MeSH terms

  • BRCA2 Protein / genetics*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • DNA Mutational Analysis
  • Disease Progression
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics
  • Fatal Outcome
  • Female
  • Germ-Line Mutation / drug effects
  • Humans
  • Liquid Biopsy
  • Liver / pathology
  • Liver Neoplasms / blood
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / secondary
  • Loss of Heterozygosity
  • Middle Aged
  • Phthalazines / pharmacology*
  • Phthalazines / therapeutic use
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Receptors, Estrogen / metabolism

Substances

  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Receptors, Estrogen
  • olaparib